Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297903 | 0.87 | CNR1 (0.80) | CNR1KCNH2 | |
| SCHEMBL4275583 | 0.87 | CNR1 (0.80) | CNR1KCNH2 | |
| SCHEMBL4394591 | 0.85 | CNR1 (0.76) | CNR1KCNH2 | |
| SCHEMBL4388162 | 0.84 | CNR1 (1.00) | CNR1KCNH2 | |
| SCHEMBL10064230 | 0.81 | CNR1 (0.68) | CNR1KCNH2 | |
| SCHEMBL932693 | 0.80 | CNR1 (0.69) | CNR1KCNH2 | |
| SCHEMBL13668472 | 0.80 | CNR1 (1.00) | CNR1KCNH2 | |
| SCHEMBL4275563 | 0.80 | CNR1 (1.00) | CNR1KCNH2 | |
| SCHEMBL13668473 | 0.80 | CNR1 (0.74) | CNR1KCNH2 | |
| SCHEMBL4399212 | 0.80 | CNR1 (0.75) | CNR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011002816-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | CNR1 3300/4885KCNH2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.